Elicera Therapeutics AB

As of June 30, 2026, Elicera Therapeutics AB carries a market capitalization of 178.19M, placing it among publicly traded companies globally. Its enterprise value stands at 120.06M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Elicera Therapeutics AB's next confirmed earnings release is scheduled for November 27, 2026.

As of June 30, 2026, Elicera Therapeutics AB has 66.74M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Elicera Therapeutics AB maintains a current ratio of 17.81, meaning it holds 17.8x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Elicera Therapeutics AB posted a negative return on equity (ROE) of -41.69, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -35.79, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 2.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Elicera Therapeutics AB's stock has declined approximately 53.87% over the past 52 weeks. The 50-day moving average sits at 2.79, while the 200-day moving average is 3.72.

Over the twelve months ended June 30, 2026, Elicera Therapeutics AB generated - - in revenue and converted that into -17.98M in net income, yielding earnings per share of -0.35. EBITDA reached -18.41M, while operating income came in at -18.41M.

These figures are as of June 30, 2026. Total book value stands at 56.25M, with working capital of 56.25M providing operational flexibility.

Elicera Therapeutics AB produced -25.75M in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -25.75M - equivalent to -0.51 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -19.02: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -24.81, meaning Elicera Therapeutics AB raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Elicera Therapeutics AB's most recent stock split took place on May 11, 2026 with a 38:39 split ratio.

As of June 30, 2026, Elicera Therapeutics AB has an Altman Z-Score of 31.79, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.